17th Oncology Update: Advances and Controversies
January 18-21, 2019

Friday, January 18, 2019

6:30am  | Registration
6:50    | Welcome Remarks
        | Merrick I. Ross, MD

Session I  | Prevention and Screening
            | Moderator: Merrick I. Ross, MD

7:00-8:15am  | Results of Lung Cancer Screening: Have Improved Outcomes Been Realized?
              | Jeremy J. Erasmus, MBBCh

            | Melanoma Primary Prevention Initiatives: Education and Legislation*
            | Jeffrey E. Gershenwald, MD

            | HPV Vaccination: Penetration, Efficacy, and Expanding the Indications*
            | Kathleen M. Schmeler, MD

            | Anal Cancer: Etiology, Epidemiology, and Prevention
            | Craig A. Messick, MD

Session II  | Outcomes and Palliative Care
            | Moderator: Merrick I. Ross, MD

8:15-9:10am  | Patient Reported Outcomes: Does This Improve the Patient Care Experience?*
              | Thomas A. Aloia, MD

            | Integrating Cancer Care Quality Into National Public Reporting and Pay-for-Performance Programs*
            | Karl Y. Bilimoria, MD

            | Early Integration of the Palliative Care Team: Impact on Outcomes*
            | Sririan Yennu, MD

Keynote Presentation
9:10-9:30am  | Anti-Cancer Living: Keys to Reduce Risk and Support Treatment*
              | Lorenzo Cohen, PhD

10:00am-Noon | Meet the Professor

Session III | Plenary Session
            | Moderator: Merrick I. Ross, MD

5:00-8:30pm  | Immunotherapy Symposium

            | PD-1 Resistance: Definitions, Frequency, and Biomarkers and Treatment Strategies
            | Hussein A. Tawbi, MD

            | Oncolytic (Intralesional) Immunotherapy: Can We Make a “Cold” Tumor “Hot”?
            | Robert H. Andtbacka, MD

            | Checkpoint Blockade and XRT: What is the Evidence for Synergism and an “Abscopal” Effect
            | James W. Welsh, MD

            | The Role of the Microbiome in the Response to Immunotherapy:
            | The “Scoop is in the Poop”
            | Jennifer Wargo, MD
Panel Q & A

Promising Actionable Biomarkers From Phase I Studies
Funda Meric-Bernstam, MD

Prospects for CAR-T and N-K Therapies in Solid Tumors
Stefan O. Ciurea, MD

Novel Nanoparticle Technology to Detect Micrometastatic Disease
Charles M. Balch, MD

Diagnosis and Management of Treatment-Related Toxicities

Cutaneous Toxicities of Targeted- and Immuno-Therapies
Joel Claveau, MD

Immune-Related Visceral Organ Toxicities
Isabella C. Glitza, MD, PhD

Lymphedema: Severity Assessment and Surgical Intervention
Edward I. Chang, MD

The lectures indicated with an * have been designated by The University of Texas MD Anderson Cancer Center for 1.75 AMA PRA Category 1 Credits™ in medical ethics and/or professional responsibility.
## Session IV
**Thoracic Oncology**  
*Moderator*: Stephen G. Swisher, MD

### 7:30-9:30am
- **Evolving Front-Line Therapy for Stage 3 NSCLC: Results of the Pacific Trial**  
  James W. Welsh, MD
- **Advances in the Treatment of Metastatic NSCLC**  
  John V. Heymach, MD, PhD
- **Survival Outcomes for Local Therapy of Oligo-Metastatic NSCLC: Surgery or Radiation Therapy**  
  Stephen G. Swisher, MD
- **New Paradigm in the Treatment of Small-Cell Lung Cancer**  
  Quynh-Nhu Nguyen, MD
- **Chemo-Radiation for Advanced Esophageal Cancer: Front-Line Results and the Role if Any for Salvage Surgery**  
  Wayne L. Hofstetter MD

**Panel Q & A**

**Case Presentations**  
*Moderator*: Stephen G. Swisher, MD  
*Panel*: All Speakers

### 10:00am-Noon
- **Meet the Professor**

## Session V
**Breast and Gynecological Cancer**  
*Moderator*: Kelly K. Hunt, MD

### 4:30-7:30pm
- **Results from the Taylor Rx Trial: Impact on Clinical Practice**  
  Mariana Chavez-MacGregor, MD
- **Novel Approaches to the Axilla in Node Positive Breast Cancer After Neo-Adjuvant Therapy**  
  Kelly K. Hunt, MD
- **New Controversies in the Treatment of Breast Cancer Patients with Residual Disease After Neo-Adjuvant Therapy**  
  Mariana Chavez-MacGregor, MD
- **Adjuvant Radiation Therapy for Breast Cancer: Current Controversies**  
  Thomas Buchholz, MD
- **Immunotherapy for Breast Cancer: Is Progress Finally Being Made?**  
  Elizabeth A. Mittendorf, MD
- **BRCA as a Biomarker for PARP Inhibition in Breast and Ovarian Cancer?**  
  Jennifer K. Litton, MD
- **Value of Establishing a Tumor Registry for Rare Gynecological Malignancies**  
  Michael M. Frumovitz, MD

**Panel Q & A**

**Case Presentations**  
*Moderator*: Rosa F. Hwang, MD  
*Panel*: All Speakers; David M. Adelman, MD; Lavinia P. Middleton, MD; Aysegul A. Sahin, MD
### Monday, January 20, 2019

<table>
<thead>
<tr>
<th>Session VI</th>
<th>Urology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Moderator:</strong> Christopher G. Wood, MD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-9:30am</td>
<td><strong>Making the Case for Treating Primary Prostate Cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Robotic Prostatectomy</strong></td>
</tr>
<tr>
<td></td>
<td>John W. Davis, MD</td>
</tr>
<tr>
<td></td>
<td><strong>External Beam Radiation</strong></td>
</tr>
<tr>
<td></td>
<td>Andrew K. Lee, MD, MPH</td>
</tr>
<tr>
<td></td>
<td><strong>MRI Guided Brachytherapy</strong></td>
</tr>
<tr>
<td></td>
<td>Steven J. Frank, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Surveillance</strong></td>
</tr>
<tr>
<td></td>
<td>Neema Navai, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Advances in Systemic Therapy for Aggressive Variant Prostate Cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Ana Aparicio, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Does Control of the Primary Tumor Improve Outcomes in Metastatic GU Cancers?</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Prostate Cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Brian F. Chapin, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Renal Cell</strong></td>
</tr>
<tr>
<td></td>
<td>Christopher G. Wood, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Debate: cNO Metastatic Testicular Cancer After BEP Chemotherapy</strong></td>
</tr>
<tr>
<td></td>
<td>Bradley C. Leibovich, MD</td>
</tr>
<tr>
<td></td>
<td>R. Houston Thompson, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Panel Q &amp; A</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Case Presentations</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Christopher G. Wood, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Panel:</strong> All Speakers</td>
</tr>
<tr>
<td>10:00am-Noon</td>
<td><strong>Meet the Professor</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>4:30-7:30pm</td>
<td><strong>Novel Neo-Adjuvant Approaches for Resectable Pancreas Cancer</strong></td>
</tr>
<tr>
<td>4:30-7:30pm</td>
<td><strong>Definitive Radiation Therapy for Hepatobiliary Cancer: Can This Replace Surgical Resection?</strong></td>
</tr>
<tr>
<td>4:30-7:30pm</td>
<td><strong>Update on the Multi-Disciplinary Management of Midgut Carcinoid Tumors</strong></td>
</tr>
<tr>
<td>4:30-7:30pm</td>
<td><strong>Evolving Strategies in the Treatment of Young-Age Colon Cancer</strong></td>
</tr>
<tr>
<td>4:30-7:30pm</td>
<td><strong>Can We Apply Lessons Learned in the Rectal Cancer to Improve Surgical Outcomes in Colon Cancer</strong></td>
</tr>
<tr>
<td>4:30-7:30pm</td>
<td><strong>The Evolving Role of HIPEC in Gastric Cancer</strong></td>
</tr>
<tr>
<td>4:30-7:30pm</td>
<td><strong>Advances in the Systemic Therapy of Gastric Cancer</strong></td>
</tr>
</tbody>
</table>

**Panel Q & A**

**Case Presentations**
Moderator: Robert A. Wolff, MD
Panel: All Speakers
### Session VIII: Cutaneous Oncology

**Moderator:** Merrick I. Ross, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 7:00-10:30am | Complete Dissection in Melanoma Patients with a Positive Sentinel Node: Is the Controversy Finally Resolved?  
Merrick I. Ross, MD |
|              | Reconstruction After Resection of Cutaneous Malignancies of the Face and Scalp:  
Preserving Aesthetics Without Compromising Oncologic Outcomes  
David M. Adelman, MD |
|              | Adjuvant and Neo-Adjuvant Therapy: Which Patients? What Therapy?  
Amaria Rodabe, MD |
|              | Front-Line Therapy for Disseminated Melanoma:  
Current Standards and Future Directions  
Michael A. Davies, MD, PhD |
|              | New Paradigm in the Treatment of Melanoma Brain Metastases:  
Are We Finally Making Progress?  
Michael A. Davies, MD, PhD |
|              | Targeted and Immunotherapy for Advanced Non-Melanoma Skin Cancer  
Michael R. Migden, MD |

**Panel Q & A**

**Case Presentations**

**Moderator:** Merrick I. Ross, MD

**Panel:** All Speakers; Robert H. Andtbacka, MD; Ana M. Ciurea, MD; Jeffrey E. Gershenwald, MD; Victor G. Prieto, MD, PhD

**Adjournment**

*Presentations have been awarded ethics credit*
GOAL
The treatment of solid tumors continues to evolve and clinicians must stay abreast of the current information and recent therapeutic advances. Many tumor types require multidisciplinary treatment; many therapies previously studied only in advanced and metastatic settings are now applied in early curative stages as well. Healthcare professionals who care for cancer patients in different stages of disease need to understand the basis for these therapies. Additionally, HCPs must apply the preclinical and clinical data supporting the development and integration of these new therapies into their clinical practice.

This educational conference will interactively address current management controversies, updates, and novel therapies for multiple tumor types. It will bring together experts from multiple disciplines involved in the treatment of various solid tumors. The expected outcome is further integration of new cancer care developments into the clinical practice of surgeons, medical oncologists, radiation oncologists, and allied healthcare professionals who care for cancer patients.

EDUCATIONAL OBJECTIVES
After attending the conference, participants should be able to:

- Incorporate an appropriate sequence for surgical, radiation and chemotherapeutic intervention into treatment (Knowledge, Competence, Performance);
- Utilize different surgical, radiation, and systemic treatments including molecularly targeted therapies for these cancers at various stages of disease to improve patient outcomes (Knowledge, Competence, Performance, Patient Outcomes);
- Illustrate and implement the optimal treatment approach when given patient scenarios representing a range of stages, prognostic markers, and clinical presentations (Knowledge, Competence, Performance, Patient Outcomes);
- Interpret the clinical effectiveness of different treatment modalities based upon efficacy and toxicity parameters to ensure the most effective guidelines and outcome measurements (Knowledge, Competence, Performance, Patient Outcomes);

TARGET AUDIENCE
This program will be of interest to surgical oncologists, medical oncologists, radiation oncologists, diagnostic radiologists, pathologists, resident trainees, primary care physicians, advanced healthcare practitioners, physician assistants, nurses, fellows, and residents involved in oncologic care.

EDUCATIONAL METHODS
Lectures • Question and Answer Sessions • Case Studies • Meet-the-Professor Sessions • Audience Response System

EVALUATION
A course evaluation survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvements activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION/CREDIT DESIGNATION
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 26.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ETHICS
The presentations marked with an asterisk (*) have been designated by The University of Texas MD Anderson Cancer Center for a total of 1.75 AMA PRA Category Credits™ in medical ethics and/or professional responsibility.